<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03324581</url>
  </required_header>
  <id_info>
    <org_study_id>277-201-00001</org_study_id>
    <nct_id>NCT03324581</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Active- and Placebo-controlled Trial of the Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A trial to assess the safety and efficacy of OPC-64005 in the treatment of Adult
      Attention-deficit/Hyperactivity Disorder
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, randomized, double-blind, active- and placebo-controlled, parallel-design
      trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conners' Adult ADHD Rating Scales-Observer: Screening Version (CAARS-O:SV) [Efficacy]</measure>
    <time_frame>Up to 56 days or early termination</time_frame>
    <description>18-item ADHD symptom score will be assessed to compare experimental group to active comparator; Total Score: Min score: 0, Max score: 54. Individual item scores: Min score: 0, max score: 3. Best outcome - Score = 0, Worse outcome - Score = 3. Total score is sum of individual scores.</description>
  </primary_outcome>
  <other_outcome>
    <measure>CAARS-O:SV</measure>
    <time_frame>Up to 56 days or early termination</time_frame>
    <description>Change in score will be assessed on experimental versus active comparator &amp; placebo. Total Score: Minimum: 0, Maximum: 54. Individual Score: Minimum: 0, Maximum: 3. Score of 0 is best outcome, score of 3 is worse outcome. Total score is sum of individual scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adult ADHD Investigator Symptom Rating Scale (AISRS) With Adult Prompts</measure>
    <time_frame>Up to 56 days or early termination</time_frame>
    <description>Change in score will be assessed on experimental versus active comparator &amp; placebo. Total Score: Minimum: 0, maximum: 54. Individual scores: minimum: 0, maximum: 3. Score of 0 is best outcome, score of 3 is worse outcome. Total score is sum of individual scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Global Impression -Severity of Illness Scale (CGI-S) Score</measure>
    <time_frame>Up to 56 days or early termination</time_frame>
    <description>Change in score will be assessed on experimental versus active comparator &amp; placebo. Minimum Score: 1, Maximum Score: 7. Score of 1 is best outcome, score of 7 is worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Global Impression - Global Improvement Scale (CGI-I) Score</measure>
    <time_frame>Up to 56 days or early termination</time_frame>
    <description>Change in score will be assessed on experimental versus active comparator &amp; placebo. Minimum Score: 1, Maximum Score: 7. Score of 1 is best outcome, score of 7 is worse outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Conners' Adult ADHD Rating Scales-Self-Report: Screening Version (CAARS-S:SV)</measure>
    <time_frame>Up to 56 days or early termination</time_frame>
    <description>Change in score will be assessed on experimental versus active comparator &amp; placebo. Total Score: Minimum: 0, Maximum: 54. Individual Score: Minimum: 0, Maximum: 3. Score of 0 is best outcome, score of 3 is worse outcome. Total score is sum of individual scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adult ADHD Quality of Life Scale (AAQoL)</measure>
    <time_frame>Up to 56 days or early termination</time_frame>
    <description>Change in score will be assessed on experimental versus active comparator &amp; placebo. 6 item scale; Individual Score: Minimum: 1, Maximum: 5 additional option of &quot;not applicable&quot; for 1 sub-question. Outcome measure vary by question, some will be: 1 - best outcome, 5 - worse outcome; others will be 1 - worse outcome, 5 - best outcome.</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug Effects Questionnaire (DEQ)</measure>
    <time_frame>Up to 56 days or early termination</time_frame>
    <description>Change in score will be assessed on experimental versus active comparator &amp; placebo to determine potential for abuse liability and dependence. Visual analog scale from 0 to 100. Scale is not quantifiable by &quot;better&quot; or &quot;worse&quot; as it is a subjective question on the subject's feelings about the medication.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Adult Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>OPC-64005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg tablet dose, titrated up to a max of 30 mg, daily, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atomoxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg capsule titrated up to 80 mg, daily, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>tablet/capsule, daily, oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-64005</intervention_name>
    <description>Tablet</description>
    <arm_group_label>OPC-64005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine</intervention_name>
    <description>Capsule</description>
    <arm_group_label>Atomoxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet/Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Screening):

          -  Male and female outpatients 18 to 55 years of age, inclusive, at the time of informed
             consent.

          -  Subjects with a primary Diagnostic and Statistical Manual of Mental Disorders, 5th
             edition (DSM-5) diagnosis of ADHD (including predominantly inattentive presentation,
             hyperactive presentation, and combined presentations) as confirmed by the Adult ADHD
             Clinical Diagnostic Scale (ACDS) v 1.2.

          -  Subjects willing to discontinue all prohibited psychotropic medication starting from
             the time of signing the informed consent and up to the 30 (+ 2)-day follow-up period.

        Exclusion Criteria:

          -  Subjects with a history of inadequate response or suboptimal tolerability to
             atomoxetine.

          -  Subjects who report allergies (lifetime treatment history) to stimulant or
             nonstimulant ADHD medications.

          -  Subjects with other DSM-5 disorders including psychosis (current or lifetime), bipolar
             disorder (current or lifetime), current major depressive disorder, or current panic
             disorder; or another psychiatric diagnosis that the investigator believes is primary
             or that will confound efficacy or safety assessments of the trail or interfere with
             participation in the trial otherwise.

          -  Subjects with a clinically significant current DSM-5 diagnosis of borderline,
             antisocial, paranoid, schizoid, schizotypal, histrionic, narcissistic, avoidant,
             obsessive compulsive, or dependent personality disorders.

          -  Subjects who currently have clinically significant dermatological, neurological,
             hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or
             gastrointestinal disorders such as any history of myocardial infarction, congestive
             heart failure, HIV seropositive status/acquired immunodeficiency syndrome, or active
             or chronic hepatitis B or C.

          -  Subjects with a history of obstructive sleep apnea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Oertli</last_name>
    <phone>919-561-2750</phone>
    <email>Jennifer.Oertli@INCResearch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern California Research, LLC</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network, LLC.</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MCB Clinical Research Centers, LLC</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research, Inc.</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Behavioral Clinical Research, Inc.</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Behavioral Research Center</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Psychiatric Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premier Psychiatric Research Institute, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eastside Comprehensive Medical Center, LLC.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Medical Research Network, LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IPS Research Company</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paradigm Research Professionals</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigators, Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Center for Clinical Investigators, Inc.</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BTC of Lincoln</name>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <zip>02865</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of the Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Aspen Clinical Research</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatric Associates</name>
      <address>
        <city>Woodstock</city>
        <state>Vermont</state>
        <zip>05091</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>ADD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

